Roche’s Tecentriq has ushered in a new era, offering the first immunotherapy option for non-small cell lung cancer (NSCLC) patients right after tumour surgery. But …
Bristol Myers Squibb boasts a historic go-ahead for Opdivo plus chemotherapy as the first immunotherapy regimen for previously untreated stomach cancer. But the PD-1 inhibitor …
David G. Maloney, MD, PhD, medical director of immunotherapy at the Seattle Cancer Care Alliance and member of Fred Hutchinson Research Center, discusses the clinical …
Medical oncologist Dr. Bernardo Goulart at the Seattle Cancer Care Alliance (SCCA) believes his latest clinical trial might be the most curative approach to treatment …
NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it will cooperate …
OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug …
Plasticell, a developer of innovative stem cell technologies and cell therapies, today announced it will collaborate with Anthony Nolan, a leading research organisation dedicated to …
Clinical-stage biotechnology company Arcus Biosciences has completed a $107m series C financing, bringing the total equity capital to around $227m. The proceeds from this financing …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
